Platform Therapeutics files Form D for $4 million equity offering
The Andover, Massachusetts biotech reported $1.75 million raised from one investor as of a August 12, 2026 first sale date.
Platform Therapeutics, Inc., based in Andover, Massachusetts, filed a Form D with the Securities and Exchange Commission covering a new notice of exempt securities offering. The filing lists a date of first sale of August 12, 2026.1
The total offering amount is $4,000,000, with $1,750,000 already sold and $2,250,000 remaining to be sold.1 The company reported that one investor has already put money into the offering.1 The minimum investment accepted from any outside investor is listed as $0.1
The security type offered is equity.1 The company claimed the Rule 506(b) exemption under Regulation D.1 The filing states this offering is not being made in connection with a merger, acquisition, or exchange offer.
Platform Therapeutics was incorporated in Delaware in 2022.1 It is classified in the biotechnology segment of the health care industry group.1 The issuer reported no revenues and no aggregate net asset value, and its issuer size was marked not applicable.1
James Wilkie is listed as an executive officer and director, and Lakhmir Chawla is listed as a director, both with addresses at 300 Brickstone Square, Suite 201, Andover, Massachusetts.1 The filing reports $0 in sales commissions and $0 in finders' fees.1 Proceeds directed to executive officers, directors, or promoters named in the filing were also reported at $0.1
The notice was signed by James Wilkie, Chief Executive Officer, dated August 27, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.